SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- iSpecimen Founder and CEO Christopher Ianelli, MD, PhD, will co-present on the emerging technologies and industry perspectives in molecular medicine on Wednesday, Feb. 14 at Molecular Med TRICON in San Francisco.
Since the event's inception in 1993, the annual Molecular Medicine Tri-Conference has become one of the world's leading international events in the fields of drug discovery, development and diagnostics. It runs Feb. 11-16 and is expected to gather 3,700 global experts in biotech, pharma and academia.
The plenary session, called "Emerging Technologies and Industry Perspectives," will take place at 8:45 a.m. PST. The panel session will feature a series of presentations on emerging technologies in molecular medicine. Prior to a moderated Q&A, Dr. Ianelli will present solutions in biospecimen procurement that are fulfilling the needs of medical researchers who need high-quality samples – including tissue, biofluids and cells – for discovery and development applications in molecular medicine.
The panel will be moderated by:
- Kristin Ciriello Pothier, Global Head of Life Sciences, Parthenon-EY
- Scott Palmer, Senior Vice President and Head of Precision Medicine, Parthenon-EY
And, fellow panelists include:
- Martha Najib, Vice President, Business Development, Ximedica
- Christopher Mueller, PhD, President & CTO, Lab7 Systems
- Florian Bell, Senior Member, Technical Staff, Sensor System Integration, Qorvo
- Tim Wesselman, CEO, OnRamp Bioinformatics Inc
- Erik Vossenaar, PhD,Vice President, Business Development, Biocartis
- Siamak Baharloo, PhD, Labviva
- Alessandra Cesano, Chief Medical Officer, NanoString Technologies
About iSpecimen
Headquartered in Lexington, MA, iSpecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. The privately held company has developed the iSpecimen Marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. Proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. And ultimately, healthcare advances for all. For more information about iSpecimen, please visit www.ispecimen.com.
SOURCE iSpecimen